|Day's Range||0.000 - 0.000|
|52 Week Range|
|PE Ratio (TTM)||5.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo Finance Get free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc., Albany Molecular Research, Inc. and Akorn, Inc. (MYL-US, CBM-US, ACET-US, NKTR-US, PFE-US, AMRI-US and ... Read more (Read more...)
Caesars shares sink after a judge ruled that it would not be shielded from $11 billion in bondholder lawsuits.
Click here to see latest analysisElite Pharmaceuticals, Inc. reports financial results for the year ended March 31, 2016.HighlightsGross margins widened from 27.61% to 58.80% compared to the same period last year, operating (EBITDA) margins now -61.22% from -316.83%.Change in operating cash flow of 81.69% compared to same period last year is about the same as […] (Read more...) The post Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 appeared first on CapitalCube.